Drugs of Abuse Testing
Randox have developed an innovative multi-marker drugs of abuse testing procedure for rapid drug screening programmes. The Drugs of Abuse(DoA) biochips permit the analysis of up to 10 drug classes from a single patient sample providing rapid and accurate testing.
Randox biochip array technology is based on tried and tested ELISA methods. Each 9x9mm biochip comprises up to 25 discrete test regions (DTRs) on which immobilised antibodies specific to each biomarker are contained. In addition, two DTRs are reserved for quality control testing. The Drugs of Abuse biochip arrays demonstrate superior assay performance and also show excellent correlation with GC/MS.
Two Drugs of Abuse biochip arrays are available; DoA array I contains, amphetamine, methamphetamine, barbituates, benzodiazepine 1 & 2, Cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine. DoA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, LSD, MDMA, methaqualone, oxycodone 1 & 2 and propoxyphene. As a further feature, creatinine is included on the arrays as a marker of adulteration when testing urine samples. Both biochip arrays are validated for use with urine and whole blood. The use of oral fluid as a sample matrix is validated on DoA array I and currently in development for DoA array II.
Click here to post comments
Return to Forensic Science 2.0.